Baxter Recieves Efficacy Results for Influenza Vaccine

A Phase III study has shown a near 80% efficacy of Baxter's vaccine in protecting against influenza strains.

Baxter International announced on February 15 that its Preflucel vaccine has demonstrated nearly 80% efficacy in protecting against influenza strains, as shown in a Phase III study.

The results, published in The Lancet, indicated that participants responded positively to the vaccine, with 78.5% protective efficacy against culture-confirmed influenza infection and robust immune responses, against the three viral strains contained in the vaccine, including A/H1N1, A/H3N2 and B-specific. In addition to protection, investigators found significantly reduced duration and severity of influenza symptoms in infected subjects in the vaccinated group, as compared with the placebo group in a subsequent analysis.